NFL Biosciences Announces €2.2 Million Capital Increase

NFL Biosciences, a biopharmaceutical company based in Montpellier, France, has announced a capital increase of approximately €2.2 million. This will be conducted through a global offering involving both a private placement for qualified investors and a public offering for retail investors on the PrimaryBid platform. The subscription price for new shares is set at €1.20, representing a near 25% discount on recent trading averages. Both offerings opened on May 22, 2025, and will close the same day at 10pm CEST.

The funds will support the Phase 3 clinical trial of NFL-101, their botanical-based treatment for smoking cessation. The total Phase 3 costs are estimated at €4.5 million.

The offering includes commitments like a 90-day lock-up period post-settlement. Invest Securities is coordinating the effort. While offering potential, risks include market volatility and possible dilution for investors.